Sentences with phrase «preclinical models shows»

«Novel imaging model helps reveal new therapeutic target for pancreatic cancer: Antisense treatment in preclinical models shows effectiveness against deadly tumors.»

Not exact matches

«In 2015 our research team showed that blocking a different protein in the NOD2 pathway could halt inflammation, and was able to halt the progression of multiple sclerosis in a preclinical model.

In multiple preclinical models, OMP - 54F28 (FZD8 - Fc) has shown its effectiveness in reducing CSC populations, leading to associated anti-tumor activity, either as a single agent or when combined with chemotherapy.

The other study — Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma — published March 30, shows how drugs targeting PI3K and MAPK could represent promising candidates for glioblastoma therapy.

Using all the existing data that was available, Andrechek, along with MSU doctoral student Daniel Hollern, analyzed 1,172 mouse mammary tumor samples from 26 different preclinical models and was able to compile one of the largest databases to show which strains of mice were best suited to study a particular type of human breast cancer.

«This study for the first time shows increased expression of IL - 33 in AMD and further demonstrates a role for glia - derived IL - 33 in the accumulation of myeloid cells in the outer retina, loss of photoreceptors, and functional impairment of the retina in preclinical models of retina stress,» the authors note.

Study results showed that in preclinical models tumor - to - background ratios obtained from 11C - sarcosine PET were significantly elevated compared to 11C - choline.

«Stem cell - based therapy for targeting skin - to - brain cancer: Stem cells loaded with oncolytic viruses show promising results in preclinical models for targeting skin cancer metastases in the brain.»

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

Drew Pardoll, Glenn Dranoff, Elizabeth Jaffee, Hyam Levitsky, and colleagues conduct preclinical studies showing that a vaccine composed of tumor cells irradiated and genetically modified to produce immune system growth factor GM - CSF (granulocyte - macrophage colony - stimulating factor)-- which would become known as the therapeutic cancer vaccine GVAX — could induce potent, specific, and long - lasting anti-tumor immunity in multiple mouse tumor models.

Osimertinib showed preclinical evidence of concentrations in mouse brain tissue 5 - to 25-fold higher than in plasma, [16] and has shown greater penetration of the BBB in mouse models than gefitinib, rociletinib, or afatinib.

Finally, we show that addition of small molecule inhibitors of eIF2α dephosphorylation to muscle stem cell cultures permits their ex vivo expansion and engraftment into a preclinical mouse model of Duchenne muscular dystrophy.

An AAV gene therapy approach has shown in preclinical in vivo models to produce stable gene expression, enhanced survival, and prevention of hypoglycemia.

Both induced and natural Tregs were shown to reduce GVHD in mice or preclinical models (7 — 10).

GLN - 1001 is currently in preclinical development, where it has been shown to dramatically prolong survival in patient derived xenograft animal models of glioblastoma.

Now, three papers published concurrently in Science have shown CRISPR can treat a genetic disease in a postnatal mouse model, an important proof of concept for future preclinical and clinical work.

A new generation DNA - based vaccine against Zika virus showed protection from infection, brain damage and death in a preclinical model.

Using a preclinical model of breast cancer, the researchers showed that anti-tumor cells placed via scaffold prevented relapse while intravenously administered T cells did not.

However, ADCs that use derivatives of calicheamicin, which promotes double - stranded DNA breaks, such as GO and inotuzumab ozogamicin, 40,41 have limited activity in cells with high multidrug resistance protein activity, a phenotype found in a significant fraction of AML patients.42 Another ADC, SGN - CD123A, comprising an engineered form of the CD123 - targeting 7G3 antibody conjugated to a synthetic pyrrolobenzodiazepine dimer, which acts via DNA crosslinking, has entered clinical trials after showing robust activity in preclinical models of AML, including those with multidrug resistance.33

Small peptides that mimic some of the properties of apo A-I have been shown in preclinical models to improve HDL function and reduce atherosclerosis without altering HDL - cholesterol levels.2 Eating the typical western diet appears to damage apo A-I and renders them proinflammatory and atherogenic.